THYQUIDITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050307 | VISTAPHARM | Method for the preparation of a levothyroxine solution |
Aug, 2031
(7 years from now) | |
Thyquidity is owned by Vistapharm.
Thyquidity contains Levothyroxine Sodium.
Thyquidity has a total of 1 drug patent out of which 0 drug patents have expired.
Thyquidity was authorised for market use on 30 November, 2020.
Thyquidity is available in solution;oral dosage forms.
The generics of Thyquidity are possible to be released after 06 August, 2031.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 30 November, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
How can I launch a generic of THYQUIDITY before it's drug patent expiration?
More Information on Dosage
THYQUIDITY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic